<DOC>
	<DOCNO>NCT00078858</DOCNO>
	<brief_summary>This phase I/II trial study whether stop cyclosporine mycophenolate mofetil well reduce risk life-threatening graft-versus-host disease ( GVHD ) previous approach mycophenolate mofetil stop cyclosporine . The reason study do present time curative therapy know outside stem cell transplantation type cancer . Because age underlie health status , patient may higher likelihood experience harm conventional blood stem cell transplant . This study test whether new blood stem cell transplant method make safe change order length time immune suppress drug give transplant .</brief_summary>
	<brief_title>Mycophenolate Mofetil Cyclosporine Reducing Graft-Versus-Host Disease Patients With Hematologic Malignancies Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether incidence life-threatening GVHD reduce unrelated donor peripheral blood mononuclear cell ( PBMC ) hematopoietic cell transplantation ( HCT ) use nonmyeloablative conditioning earlier discontinuation cyclosporine ( CSP ) extend administration mycophenolate mofetil ( MMF ) patient hematologic malignancy metastatic renal cell carcinoma . SECONDARY OBJECTIVES : I . To compare incidence acute chronic GVHD protocol 1463 1641 . II . To compare utilization corticosteroid protocol 1463 1641 . III . To compare survival achieve protocol 1463 1641 . OUTLINE : CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -4 -2 , undergo total-body irradiation ( TBI ) day 0 . TRANSPLANTATION : Patients undergo allogeneic PBMC transplant day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 80 taper day 150 mycophenolate mofetil PO IV thrice daily ( TID ) day 0-30 , BID day 31-150 , taper day 180 . Treatment continue absence unacceptable toxicity . After completion study treatment , patient follow periodically 24 month yearly 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ages &gt; 50 year hematologic malignancy treatable unrelated HCT Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT preexist medical condition prior therapy consider high risk regimen relate toxicity associate conventional transplant ( &gt; 40 % risk transplantrelated mortality [ TRM ] ) patient refuse conventional HCT ; transplant must approve inclusion criterion participate institution 's patient review committee Patient Care Conference ( PCC Fred Hutchinson Cancer Research Center [ FHCRC ] ) principal investigator collaborating center ; patient = &lt; 50 year age receive previous highdose transplantation require patient review committee approval ; child &lt; 12 year must discuss FHCRC primary investigator ( PI ) prior registration Patients metastatic renal cell carcinoma histologic subtypes clear cell , papillary medullary may accept regardless age The following disease permit although diagnosis consider approve PCC participate institution 's patient review committee principal investigator : Aggressive nonHodgkin lymphoma ( NHLs ) histologies diffuse large B cell NHLnot eligible autologous hematopoietic stem cell transplant ( HSCT ) , eligible conventional myeloablative HSCT , fail autologous HSCT Low grade NHL &lt; 6 month duration complete remission ( CR ) course conventional therapy Mantle cell NHLmay treat first CR Chronic lymphocytic leukemia ( CLL ) Must refractory fludarabine ; patient fail complete partial response therapy regimen contain fludarabine ( another nucleoside analog , e.g . 2cladribine [ CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain fludarabine ( another nucleoside analog ) Hodgkin disease ( HD ) must receive failed frontline therapy Multiple myeloma ( MM ) must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HCT permit Acute myeloid leukemia ( AML ) must &lt; 5 % marrow blast time transplant . Acute lymphocytic leukemia ( ALL ) must &lt; 5 % marrow blast time transplant Chronic myelogenous leukemia ( CML ) Patients accept chronic phase accelerate phase ; patient receive prior autograft high dose therapy undergone intensive chemotherapy filgrastim ( GCSF ) mobilize peripheral blood mononuclear cell ( GPBMC ) autologous conventional HCT advance CML may enrol provide CR CP &lt; 5 % marrow blast time transplant Myelodysplastic syndrome ( MDS ) /myeloproliferative disorder ( MPD ) Only patient MDS/refractory anemia ( RA ) MDS/refractory anemia ring sideroblast ( RARS ) eligible protocol ; additionally patient myeloproliferative syndrome ( MPS ) eligible ; patient MDS MPS &gt; 5 % marrow blast ( include transformation AML ) must receive cytotoxic chemotherapy achieve &lt; 5 % marrow blast time transplant Renal cell carcinoma Must evidence disease amenable surgical cure history active metastatic disease radiological histologic criterion DONOR : FHCRC match allow grade 1.0 2.1 : Unrelated donor prospectively : Matched human leukocyte antigen ( HLA ) A , B , C , major histocompatibility complex , class II , DR beta 1 ( DRB1 ) major histocompatibility complex , class II , DQ beta 1 ( DQB1 ) high resolution typing ; Only single allele disparity allow HLAA , B , C define high resolution type DONOR : A positive antidonor cytotoxic crossmatch absolute donor exclusion DONOR : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0201 , type mismatch allow DONOR : GPBMC permit HSC source protocol Patients rapidly progressive intermediate high grade NHL Renal cell carcinoma patient With expect survival le 6 month Disease result severely limited performance status ( &lt; 70 % ) Any vertebral instability History brain metastasis Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Patients nonhematological tumor except renal cell carcinoma Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Cardiac ejection fraction &lt; 35 % ; ejection fraction require history anthracycline exposure history cardiac disease Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % and/or receive supplementary continuous oxygen The FHCRC PI study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Karnofsky score &lt; 60 ( except renal cell carcinoma [ RCC ] ) Patients &gt; grade II hypertension Common Toxicity Criteria ( CTC ) Human immunodeficiency virus ( HIV ) positive patient The addition cytotoxic agent `` cytoreduction '' exception hydroxyurea imatinib mesylate allow within two week initiation condition DONOR : Marrow donor DONOR : Donors HIVpositive and/or , medical condition would result increase risk GCSF mobilization harvest GPBMC</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>